Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
20.85
+0.23 (1.12%)
May 6, 2026, 4:00 PM EDT - Market closed

Lyell Immunopharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
4866541894938661,879
Market Cap Growth
258.09%246.60%-61.70%-43.11%-53.91%-
Enterprise Value
290.26448.81-130.813.35289.021,331
Last Close Price
20.8530.7812.8038.8069.40154.80
PE Ratio
--1.92-0.49-2.07-4.69-4.21
PS Ratio
13513.4218169.603093.823789.8610.23176.41
PB Ratio
1.792.640.490.751.042.02
P/TBV Ratio
1.442.120.440.741.031.13
P/FCF Ratio
--4.34-1.16-2.96-4.47-9.80
P/OCF Ratio
--4.36-1.16-3.01-5.11-14.88
EV/Sales Ratio
8062.7012466.90-2144.4225.803.41124.94
EV/EBITDA Ratio
--1.740.39-0.01-1.71-6.62
EV/EBIT Ratio
--1.670.36-0.01-1.55-6.20
EV/FCF Ratio
--2.980.80-0.02-1.49-6.94
Debt / Equity Ratio
0.140.170.130.090.080.07
Debt / EBITDA Ratio
-0.16-0.16-0.15-0.25-0.37-0.33
Debt / FCF Ratio
-0.29-0.28-0.31-0.34-0.33-0.35
Net Debt / Equity Ratio
-0.78-0.83-0.83-0.75-0.69-0.59
Net Debt / EBITDA Ratio
0.870.800.942.163.412.73
Net Debt / FCF Ratio
1.601.361.962.942.982.86
Asset Turnover
0.000.000.000.000.080.01
Quick Ratio
6.885.006.8915.8217.2913.15
Current Ratio
7.235.287.0616.0717.5913.40
Return on Equity (ROE)
-94.43%-86.98%-66.10%-31.53%-20.77%-30.36%
Return on Assets (ROA)
-74.22%-64.85%-57.82%-29.27%-18.12%-21.10%
Return on Invested Capital (ROIC)
-497.30%-458.31%-292.85%-113.41%-50.21%-58.16%
Return on Capital Employed (ROCE)
-84.82%-74.04%-62.25%-30.57%-18.88%-22.15%
Earnings Yield
-56.41%-52.18%-204.92%-48.20%-21.33%-23.77%
FCF Yield
-31.00%-23.05%-86.29%-33.77%-22.38%-10.21%
Buyback Yield / Dilution
-30.74%-30.74%-4.18%-1.58%-81.79%-925.18%
Total Shareholder Return
-30.74%-30.74%-4.18%-1.58%-81.79%-925.18%
Updated May 6, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q